FDA Investigator Atul J Agrawal

Atul J Agrawal has inspections in 6 countries as of 18 Aug 2023. Atul J Agrawal has collaborated with a combinined 5299 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
92
Last Inspection Date:
18 Aug 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
India, United States of America, China, Japan, Singapore, Australia
Co-Investigator(s):
Addam S Reynolds, Ademola O Daramola, Adetutu M Gidado, Alan P Kurtzberg, Alberto A Viciedo, Albinus D'sa, PhD, Albinus M D Sa, Alicia M Mozzachio, Alison N Stieg, Amy L Singer, Amy M Cramer, Anastasia I Onuorah, Angela E Glenn, Ankur C Patel, Ann Marie Montemurro, Annemarie B Randow, Annemarie Bodnar, Anthony A Charity, Arie C Menachem, Arsen Karapetyan, Ashar P Parikh, Barbara J Maulfair, Barbara J Wilimczyk, Barbara Jwilimczyk Macri, Benjamin Bustamante, Brandon L Mariner, Brooke K Higgins, Brooke K Seeman, Burnell M Henry, Byungja E Marciante, Carl Lee, Carrie A Hughes, Cassandra L Abellard, CDR Ileana Barreto Pettit, Chaltu N Wakijra, Charles I Ann, Cheryl A Clausen, Christina A Miller, Christine M Cerenzio, Christopher M Jenner, Cynthia A Harris, MD, RN, Cynthia Jim, CSO, Dan Grabicki, Daniel J Grabicki, Daniel J Roberts, David E Bailey, Dawn C Olenjack, Dawn L Wydner, Deborah B Nixon, Denise M Visco, Investigator, Dennis L Doupnik, Devon Jenkins, Dhaval H Patel, Diane T Bargo, Diane T O'brien, Dipesh K Shah, Donald L Lech, Doreen P Gubbay, Douglas A Campbell, Douglas C Kovacs, Dr. Barbara D Paul, PhD, Dr. Guang Gao, PhD, Dr. Robert C Horan, MD, Dr. S Nar Ali, PhD, Edward Oshaughnessy, Emest F Bizjak, Eric J Cunningham, Eric M Mueller, PharmD, Eric Rothschild, Erika V Butler, Erin D Mccaffery, Erin L Mcfiren, Farhana Khan, Felix Maldonado, Frank J Marciniak, Freddy Ortiz Colon, Frederick Razzaghi, Gene R Gunn, Gianine E Delade, Graeme E Price, Guerlain Ulysse, Guo Q Shen, Heidy C Perales, Helen B Ricalde, Helen Verdel, Hitesh R Patel, Holly S Simms, Hyojong Kwon, PhD, Israel Santiago, OCM, Jacob G Lutz, Jacqueline Mdiaz Albertini, James A Liubicich, James M Mason, James R Birkenstamm, Jananiga Vanniyasingam, Janet A Rajan, Javier O Vega, Jawaid Hamid, Jay B Shah, Jean M Kelahan, Jeffrey P Raimondi, Jennifer A Bazergui, Jennifer Macmillan, Jesse P Hardin, Jessica M Monteiro, Jogy George, John Dan, John P Mistler, Johnna L Bleem, Jonathan S Helfgott, Jonathan W Chapman, Joohi Castelvetere, Jose Acruz Gonzalez, Jose Alopez Rubet, Jose E Melendez, DDC, Jose M Cayuela, Jose O Hernandez, Jose R Hernandez, Joseph Binhas, Joseph F Mcginnis, RPh, Joseph Mcginnis, Jot R Klena, Joy R Kozlowski, Joy Rkozlowski Klena, Juanita P Versace, June P Page, Justin A Boyd, Justine Tomasso, Karen A Spencer, Karen E D'orazio, Karen K Moksnes, Karen Takahashi, Katelyn Astaub Zamperini, Katherine Szestypalow, Keith M Reilly, Kelli F Dobilas, Kellia N Hicks, Kerry A Kurdilla, Kevin Obrien, Kham Phommachanh, Kim Lthomas Cruse, Kimberly A Coward, King, Kinh Q Mac, Ko U Min, Kristen E Rescigno, Kristy A Zielny, Kristy E Zuroski, Kshitij A Patkar, Laishan L Lam, Larry K Austin, Lauren L Vajo, Lawrence Harmon, Jr, Lawrence J Stringer, Lawrence R Johnson, Lenahan Lenahan, Peter R, Li Hongpaul Yeh, PhD, Li Li, Liatte Kreuger, PharmD, Lily Y Koo, Linda F Murphy, Linda R Kuchenthal, Lisa M Bellows, Loretta Nemchik, Lori S Lawless, Lucas B Leake, Luis A Dasta, Luis M Burgos Medero, Makini Cobourne Duval, PhD, Marcellinus D Dordunoo, Marcelo O Mangalindan, Jr, Marcus A Ray, Marcus F Yambot, Marea K Harmon, Margaret M Sands, Maria A Bienkowski, Maria A Reed, Maria Estrella, Maria Estrella Jimenez, Marie Bbuen Bigornia, Marilyn M White, Marjorie D Schultz, Martha T Olone, Massoud Motamed, Melissa J Garcia, Melissa T Roy, Meredith L Sheridan, Meyer J Slobotsky, Michael A Charles, Michael L Chasey, Michael R Fox, Michael R Goga, Michael R Klapal, Michael Serrano, Michelle M Parisi, Michelle Marsh, Miguel A Martinez, Mina D Ahmadi, Mindy M Chou, Monika Borkowska, Muralidhara B Gavini, PhD, Nadeem I Chaudhry, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Natasha Gupta, Nebil A Oumer, Nerizza B Guerin, Nicholas A Violand, Niketa Patel, Omotunde O Osunsanmi, Paraluman S Leonin, Parul M Patel, Patrick C Klotzbuecher, Patrick J Campbell, Paul L Bellamy, Paul Mouris, Paula A Trost, Paula J Bretz, Peter E Baker, Peter R Lenahan, Prabhu P Raju, Pratik S Upadhyay, DDC, Qin Xu, Rabin N Ghoshal, Rachel A Gomez, Rafael E Arroyo, Rajiv R Srivastava, Ralph A Erickson, Raymond L Cheung, Raymond T Oji, Rebecca E Dombrowski, Rebecca Rodriguez, Regina T Brown, Rita K Kabaso, Robert D Tollefsen, Robert M Barbosa, Rose Ljean Mary, Rose M Ashley, Russell J Glapion, Saied A Asbagh, Saleem A Akhtar, Samir C Gala, Sandra A Hughes, Sandra Kershaw, Sangeeta M Khurana, PhD, Sarah Adella Fave, Sarah Forney, Satheesh K Podaralla, Satheesh Thomas, Schultz, Scott N Lim, Scott T Ballard, Sean G Casey, Sean R Marcsisin, Sharon K Thoma, PharmD, Sherri J Liu, Shirley S Wen, Shirshendu K Deb, PhD, Simone E Pitts, Sinai Davis, Sneha Patel, Sneha S Patel, Sri Ramakrishnaiah Yellela, State Agency, Stephanie L Shapley, Stephanie T Durso, Stephen D Brown, Stephen J Koniers, Stephen J Mottola, Steven P Donald, Sue Lee Chan, Susan D Yuscius, Susan M Halsted, Susan M Jackson, Susan W Ting, Susanna E Ford, Analyst, Syed N Ali, Tamika White, Tamil Arasu, PhD, Tara G Bizjak, Tara R Gooen, Thomas J Arista, Tonia F Bernard, Toyin B Oladimeji, Unnee Ranjan, Valerie C Reed, Victoria Spivak, Wayne J Meyer, William A Warnick, William H Linkroum, William J Muszynski, William L Bargo, Willy A Orantes, Xiomara Copeland, Yasamin Ameri, Yvesna C Blaise, Yvins Dezan, Zhaohui Ye, Zhongren Wu

Atul J Agrawal's Documents

Publish Date Document Type Title
February, 2011 EIR Everest Life Sciences LLC - EIR, 2011-02-18
June, 2013 FDA 483 USV Private Limited - Form 483, 2013-06-11
November, 2009 FDA 483 Davion, Inc - Form 483, 2009-11-19
April, 2013 FDA 483 Canton Laboratories Pvt. Ltd. - Form 483, 2013-04-09
February, 2011 FDA 483 Everest Life Sciences LLC - Form 483, 2011-02-18
August, 2015 FDA 483 Concept Products Limited - Form 483, 2015-08-05
April, 2010 FDA 483 Vantage Specialty Ingredients, Inc - Form 483, 2010-04-08
January, 2013 FDA 483 RPG Life Sciences Limited - Form 483, 2013-01-31
February, 2019 FDA 483 Shree Mahadev Intermediate - Form 483, 2019-02-07
November, 2016 FDA 483 Response Mylan Pharmaceuticals Inc. - Form 483R, 2017-02-13
January, 2011 FDA 483 Cispharma Inc. - Form 483, 2011-01-24
June, 2013 EIR USV Private Limited - EIR, 2013-06-11
February, 2012 EIR Nutro Laboratories, a div of NBTY, Inc. - EIR, 2012-02-24
October, 2013 EIR Smruthi Organics Limited - EIR, 2013-10-18
June, 2009 FDA 483 Propak Development, Inc. - Form 483, 2009-06-17
July, 2013 FDA 483 Wockhardt Limited - Form 483, 2013-07-30
November, 2012 FDA 483 AARTI DRUGS LTD - Form 483, 2012-11-02
August, 2021 EIR Indiana Chem-Port - EIR, 2021-08-07
December, 2018 FDA 483 Eugia Pharma Specialities Limited - Form 483, 2018-12-14
June, 2010 FDA 483 Tri-Med Laboratories Inc - Form 483, 2010-06-21
November, 2018 EIR Annora Pharma Private Limited - EIR, 2018-11-10
August, 2010 FDA 483 Loricon Testing Service, Inc. - Form 483, 2010-08-12
November, 2010 FDA 483 Ohm Laboratories Inc. - Form 483, 2010-11-10
October, 2013 FDA 483 Smruthi Organics Limited - Form 483, 2013-10-18
April, 2010 FDA 483 Colgate-Palmolive Company - Form 483, 2010-04-30
April, 2012 EIR Cispharma Inc. - EIR, 2012-04-23
March, 2014 FDA 483 Ohm Laboratories Inc. - Form 483, 2014-03-18
May, 2009 FDA 483 Response RMJ Laboratories, Inc. - Form 483R, 2009-05-28
December, 2012 FDA 483 Sun Pharmaceutical Industries Limited - Form 483, 2012-12-14
April, 2012 FDA 483 Cispharma Inc. - Form 483, 2012-04-23
May, 2009 FDA 483 RMJ Laboratories, Inc. - Form 483, 2009-05-28
August, 2015 FDA 483 YUXING BIOTECHNOLOGY(GROUP) CO.,LTD. - Form 483, 2015-08-21
October, 2009 FDA 483 VILS Pharma Coating LLC - Form 483, 2009-10-16
March, 2019 EIR MSD International GmbH (Singapore Branch) - EIR, 2019-03-08
November, 2016 EIR Mylan Pharmaceuticals Inc. - EIR, 2016-11-18
November, 2011 FDA 483 Roche Molecular Systems, Inc. - Form 483, 2011-11-01
July, 2010 EIR Bayer HealthCare LLC - EIR, 2010-07-30
February, 2011 FDA 483 Response Everest Life Sciences LLC - Form 483R, 2011-03-09
July, 2010 FDA 483 Cosmax USA, Inc. (Cosmax USA, Corporation) - Form 483, 2010-07-19
April, 2018 FDA 483 Response Mylan Pharmaceuticals Inc. - Form 483R, 2018-05-03
August, 2018 FDA 483 Akorn Operating Company LLC (dba Akorn) - Form 483, 2018-08-30
January, 2013 FDA 483 Unique Chemicals - Form 483, 2013-01-31
April, 2021 FDA 483 Cyclomedica Australia Pty Limited - Form 483, 2021-04-06
September, 2011 FDA 483 Apicore US LLC - Form 483, 2011-10-24
July, 2013 FDA 483 Wockhardt Limited - Form 483, 2013-07-31
March, 2014 EIR OHM LABORATORIES INC. - EIR, 2014-03-18
August, 2019 EIR SIONC PHARMACEUTICAL PRIVATE LIMITED - EIR, 2019-08-02
February, 2019 EIR Shree Mahadev Intermediate - EIR, 2019-02-07
November, 2016 FDA 483 Mylan Pharmaceuticals Inc. - Form 483, 2016-11-18
March, 2010 FDA 483 Hikma Pharmaceuticals USA, Inc. - Form 483, 2010-03-01
January, 2010 FDA 483 Rebgro Corporation - Form 483, 2010-01-15
November, 2019 FDA 483 Vega Life Sciences - Form 483, 2019-11-28
September, 2009 FDA 483 Equinox Packaging Inc. - Form 483, 2009-09-11
August, 2019 FDA 483 Response SIONC PHARMACEUTICAL PRIVATE LIMITED - Form 483R, 2019-08-02
April, 2013 EIR Canton Laboratories Pvt. Ltd. - EIR, 2013-04-09
July, 2009 FDA 483 Sunrise Pharmaceutical Inc - Form 483, 2009-07-30
March, 2019 FDA 483 Response MSD International GmbH (Singapore Branch) - Form 483R, 2019-03-08
March, 2014 FDA 483 OHM LABORATORIES INC. - Form 483, 2014-03-18
March, 2019 FDA 483 MSD International GmbH (Singapore Branch) - Form 483, 2019-03-08
April, 2018 FDA 483 Mylan Pharmaceuticals Inc. - Form 483, 2018-04-12
August, 2019 FDA 483 SIONC PHARMACEUTICAL PRIVATE LIMITED - Form 483, 2019-08-02
August, 2021 FDA 483 Indiana Chem-Port - Form 483, 2021-08-07

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more